Opexa Therapeutics Inc  

(Public, NASDAQ:OPXA)   Watch this stock  
Find more results for OPXA
1.63
-0.02 (-1.51%)
Apr 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.62 - 1.70
52 week 1.25 - 3.70
Open 1.65
Vol / Avg. 157,641.00/686,258.00
Mkt cap 44.90M
P/E     -
Div/yield     -
EPS -1.50
Shares 27.55M
Beta 2.41
Inst. own 5%
Apr 23, 2014
OPEXA THERAPEUTICS INC at Redchip Virtual Conference
Feb 12, 2014
OPEXA THERAPEUTICS INC at Leerink Swann Global Healthcare Conference
Feb 10, 2014
OPEXA THERAPEUTICS INC at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1077.42% -1315.03%
Operating margin -1079.03% -1140.20%
EBITD margin - -914.67%
Return on average assets -61.50% -109.63%
Return on average equity -80.80% -141.99%
Employees 26 -
CDP Score - -

Address

2635 Technology Forest Blvd.
THE WOODLANDS, TX 77381
United States - Map
+1-281-7750600 (Phone)
+1-281-8728585 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.

Officers and directors

Neil K. Warma President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Karthik Radhakrishnan CFA Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Don G. Healey Ph.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Donna R. Rill Chief Development Officer
Age: 59
Bio & Compensation  - Reuters
Timothy C. Barabe Director
Age: 60
Bio & Compensation  - Reuters
Hans-Peter Hartung M.D., Ph.D. Director
Bio & Compensation  - Reuters
Gail J. Maderis Independent Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Richman Independent Director
Age: 52
Bio & Compensation  - Reuters
Scott B. Seaman CPA Independent Director
Age: 57
Bio & Compensation  - Reuters